The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: Results from the estrogen in women with atherosclerosis study
E. Hoibraaten et al., The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: Results from the estrogen in women with atherosclerosis study, THROMB RES, 98(1), 2000, pp. 19-27
Data on the effect of hormone replacement therapy on hemostasis are inconsi
stent, and there are few data in women with coronary artery disease. In a s
ingle-center, open, randomized study, 118 postmenopausal women with angiogr
aphically verified coronary artery disease were randomized to hormone repla
cement therapy, given as long-cycle transdermal 17-beta-estradiol (50 mu g/
24 hour) for 3 months with sequential medroxy-progesterone acetate for 14 d
ays, or to a control group receiving no therapy. Hemostatic parameters were
measured at baseline and after 3 and 12 months of therapy. The coagulation
inhibitors antithrombin, protein C, and protein S, but not tissue factor p
athway inhibitor, decreased significantly from baseline in the hormone repl
acement therapy group at both 3 and 12 months as compared with the control
group. The absolute decreases within the hormone replacement therapy group
were 3 to 10%, No significant differences between the two treatment groups
were observed for the coagulation products prothrombin fragment 1+2 or thro
mbin-antithrombin complex or for D-dimer, although there were significant d
ecreases in the levels within the hormone replacement therapy group. Levels
of fibrinogen, activated factor VII, and factor VII antigen were not signi
ficantly influenced by hormone replacement therapy treatment. Similarly, no
nsignificant changes were detected for the fibrinolytic parameters tissue p
lasminogen activator activity, tissue plasminogen activator antigen, and gl
obal fibrinolytic activity, but plasminogen activator inhibitor type 1 was
significantly lower in the hormone replacement therapy group due to a quest
ionable increase in the levels in the control group. In conclusion, treatme
nt with transdermal estradiol combined with long-cycle progestins was assoc
iated with no net activation of coagulation despite reduced levels of coagu
lation inhibitors. (C) 2000 Elsevier Science Ltd. All rights reserved.